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ABSTRACT
RUNX2, a master regulator of osteogenesis, is oncogenic in the
lymphoid lineage; however, little is known about its role in epithelial
cancers. Upregulation of RUNX2 in cell lines correlates with
increased invasiveness and the capacity to form osteolytic disease
in models of breast and prostate cancer. However, most studies have
analysed the effects of this gene in a limited number of cell lines and
its role in primary breast cancer has not been resolved. Using a
human tumour tissue microarray, we show that high RUNX2
expression is significantly associated with oestrogen receptor
(ER)/progesterone receptor (PR)/HER2-negative breast cancers and
that patients with high RUNX2 expression have a poorer survival rate
than those with negative or low expression. We confirm RUNX2 as a
gene that has a potentially important functional role in triple-negative
breast cancer. To investigate the role of this gene in breast cancer,
we made a transgenic model in which Runx2 is specifically
expressed in murine mammary epithelium under the control of the
mouse mammary tumour virus (MMTV) promoter. We show that
ectopic Runx2 perturbs normal development in pubertal and lactating
animals, delaying ductal elongation and inhibiting lobular alveolar
differentiation. We also show that the Runx2 transgene elicits age-
related, pre-neoplastic changes in the mammary epithelium of older
transgenic animals, suggesting that elevated RUNX2 expression
renders such tissue more susceptible to oncogenic changes and
providing further evidence that this gene might have an important,
context-dependent role in breast cancer.
KEY WORDS: RUNX2, Breast cancer, Transgenic model, Mammary
development
INTRODUCTION
The RUNX transcription factors are a closely related family of
genes implicated in a number of cancers (Blyth et al., 2005). These
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genes (RUNX1, RUNX2 and RUNX3) exhibit context-dependent
oncogenic and tumour-suppressive properties through pertinent
effects on cell growth and viability. RUNX1 is a common target for
chromosomal translocation and mutation in leukaemia, whereas
RUNX3 function is reportedly lost in epithelial cancers (Blyth et
al., 2005; Chuang and Ito, 2010; Mangan and Speck, 2011). In
contrast to these putative tumour-suppressor properties, all three
genes promote lymphoma development in mice (Cameron and
Neil, 2004; Castilla et al., 2004; Stewart et al., 1997), a pro-
oncogenic function confirmed for Runx1 and Runx2 using
transgenic models (Blyth et al., 2009; Blyth et al., 2001; Vaillant
et al., 1999). Although oncogenic in the lymphoid compartment,
very little is known about the role of RUNX2 in epithelial cancers.
Most studies have assessed its role in breast and prostate cancer
cell lines (Blyth et al., 2010; Pratap et al., 2011; Shore, 2005).
RUNX2 is upregulated in metastatic breast cancer cell lines
(Barnes et al., 2003; Nagaraja et al., 2006) and its inhibition in
MDA-MB-231 cells reduces invasive capacity in vitro, and
decreases osteolytic disease and tumour growth in vivo (Barnes et
al., 2004; Javed et al., 2005; Pratap et al., 2009). Overexpressing
Runx2 in cell lines increases invasiveness and induces a
transformed phenotype in 3D culture models, where cells become
more proliferative and less polarised (Pratap et al., 2009). RUNX2
also regulates genes associated with tumour cell migration,
metastasis and angiogenesis, such as those encoding bone
sialoprotein, osteopontin, matrix metalloproteinases and vascular
endothelial growth factor (Pratap et al., 2005; Pratap et al., 2011).
Furthermore, because RUNX2 is essential for osteogenesis, it has
been suggested that association with cancers that preferentially
metastasise to bone might be due to osteomimicry (Barnes et al.,
2003). However, the direct impact of RUNX2 in epithelial lineages
in vivo has never been tested.
To assess the role of RUNX2 in breast cancer we assessed
expression in a human tissue microarray (TMA). We find that
RUNX2 is overexpressed in a particular subset of breast cancers
that are oestrogen receptor (ER)/progesterone receptor
(PR)/HER2-negative, and that high expression of RUNX2 is
associated with poorer patient survival. To model overexpression
in vivo we generated a novel transgenic line directly assessing the
role of RUNX2 in the context of primary mammary tissue.
Transgenic expression perturbs normal development in mouse
mammary gland, demonstrating that levels of Runx2 must be
tightly regulated for normal mammary development to occur.
Furthermore, Runx2 transgenic mice develop late-onset
hyperplastic changes in the mammary gland, suggesting that
overexpression of RUNX2 renders epithelial tissues more
susceptible to pre-neoplastic changes.
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RESULTS
RUNX2 expression specifically correlates with ER/PR/HER2-
negative breast cancer
We assessed expression of RUNX2 in a cohort of human breast
cancers using a tissue array (TMA-1). In samples of normal breast
tissue examined, we detected negligible expression of RUNX2 with
only occasional cells positive for the protein. Positive RUNX2
staining was detected in the epithelium of a proportion of tumours
(67/416) and scored as negative in the remaining patients. Overall,
RUNX2 expression was not associated with disease-specific
survival, or with tumour grade, tumour size or lymph node status.
Within the RUNX2-positive cohort there was a large group of
patients displaying a low histoscore (Fig. 1A), raising concern over
the functional significance of RUNX2 in these samples, especially
in light of the fact that, in normal specimens, we observed
occasional positive cells. We therefore applied a cut-off of weighted
histoscore of 25 in the training set (TMA-1) and carried out Kaplan-
Meier analysis (Fig. 1B), comparing tumours with high RUNX2
(histoscore >25) and negative/low RUNX2 (histoscore <25).
Patients with breast cancers expressing high levels of RUNX2 had
shorter overall survival (Fig. 1B; mean survival 130 months in
RUNX2-high versus mean survival 152 months in RUNX2-
low/negative). Owing to the small number of RUNX2-positive
tumours, these results fail to reach statistical significance and
warrant validation in a larger independent cohort. Importantly,
RUNX2-expressing tumours were expressed at a significantly higher
rate in ER-negative (13/131; 10%) compared with ER-positive
(9/281; 3%) breast cancers (Fig. 1C,D; P=0.005; chi-square test).
Furthermore, many (13/22) of the RUNX2-high tumours were
negative for ER, PR and HER2 (the so-called triple-negative
subtype). RUNX2-high tumours accounted for 13 of 84 (15%)
triple-negative cancers in the cohort (Fig. 1D; P=0.008; chi-square
test). High RUNX2 expression lowered mean survival of the triple-
negative cohort from 137 to 119 months. We validated these results
in a second independent TMA (TMA-2), using the same cut-off of
weighted histoscore 25. In this cohort, which had an overall worse
prognosis, high RUNX2 expression in ER/PR/HER2-negative
tumours (7/38) was associated with a reduction in mean survival
from 81 to 59 months. Assessment of clinicopathological
characteristics showed that RUNX2-high tumours significantly
associated with ER-negative (P<0.005) and PR-negative (P<0.002)
status, and with rare breast cancer types (P<0.05; Table 1). There
was no association with age, tumour size, Ki-67 or TUNEL, but
there was a trend to more necrotic tumours (68% vs 53%) and with
increased immune cell infiltrate (54.5% vs 37%; Table 1). Although
these results will need testing in a larger cohort, it is tentative to say
that RUNX2 could serve as a putative prognostic marker within the
triple-negative subtype, which is valuable given the limited
biomarkers and therapeutic treatment options available to this
patient subset.
Overexpression of Runx2 perturbs development of virgin
mammary glands in a transgenic model
Despite being known to regulate specific mammary genes and being
expressed in some breast cancer cell lines, very little is known about
the normal function of RUNX2 in mammary gland development. To
explore this we first examined endogenous Runx2 expression in
murine mammary gland during different physiological phases.
Runx2 is expressed in virgin, early pregnant and involuting glands,
with levels decreasing during late pregnancy and lactation (Fig. 2A)
(Blyth et al., 2010). To further dissect expression of Runx2 in
specific mammary cell types, we isolated basal/myoepithelial
(lin–CD29hiCD24+) and luminal epithelial (lin–CD29loCD24+) cells
from wild-type (WT) pubertal mice on the basis of surface-marker
expression and fluorescence-activated cell sorting (Shackleton et al.,
2006). Expression of Runx2 was fourfold greater in
basal/myoepithelial cells compared with luminal epithelial cells
(Fig. 2B). These results are consistent with studies from the Smalley
lab where microarray and qRT-PCR analysis found Runx2 in sorted
basal/myoepithelial populations (Kendrick et al., 2008; Molyneux
et al., 2010). Runx1 was also higher in this population and, in
agreement with what we (Blyth et al., 2010) and others (Wang et al.,
2011) have shown, Runx1 is the most highly expressed of the Runx
genes in mammary epithelial cells. Runx3 was not detected in sorted
mammary epithelial cells (Fig. 2B).
Our TMA results indicated that high-level RUNX2 expression
could be a marker for a subset of cancers with poor prognosis. To
investigate the effects of deregulated expression, we generated a
novel transgenic model by targeting Runx2 to mammary epithelium
using the mouse mammary tumour virus (MMTV) promoter
(MMTV-Runx2). Germline transmission was achieved in two
founder lines, and transgene expression confirmed (supplementary
material Fig. S1). Development of the murine mammary gland
begins after birth, when terminal end bud structures migrate through
the fat pad until the entire gland is filled with an epithelial structure.
This process was perturbed in the Runx2 transgenic mice. When
comparing MMTV-Runx2 females to weight-matched 6-week-old
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TRANSLATIONAL IMPACT
Clinical issue
The RUNX2 transcription factor, known to be oncogenic in the T-cell
lineage, is upregulated in human breast cancer cell lines and correlates
with invasive properties in these cells. However, studies of this
transcription factor have been limited to a small number of cell lines, and
the role of RUNX2 as a putative oncogene in primary breast cancer has
not been demonstrated in vivo. There is also a lack of information on the
effect of RUNX2 expression on normal mammary epithelium. Triple-
negative breast cancer is a subtype of breast cancer for which there is
no good molecular biomarker or targeted therapeutic approach. Because
this subgroup often correlates with poor prognosis, there is an urgent
clinical need to identify underlying molecular mechanisms that would aid
in treating individuals with this aggressive form of breast cancer.
Results
To explore the role of RUNX2 in breast cancer, the authors assessed
expression of the gene in a cohort of human breast cancers using a
tissue microarray. They report that high expression of RUNX2 is limited
to a small number of primary operable breast cancers. However, high
RUNX2 expression specifically associates with the triple-negative
subtype and correlates with poorer patient survival. To further validate
the putative oncogenic properties of this gene in vivo, a transgenic
mouse model was generated in which Runx2 was targeted to the
mammary epithelium. Transgenic Runx2 predisposes primary tissue to
late-onset pre-neoplastic changes, and supra-physiological expression
perturbed normal mammary development and function. 
Implications and future directions
This study demonstrates that RUNX2 expression significantly associates
with triple-negative breast cancer. Whether RUNX2 is acting as a neutral
biomarker for this poor prognostic subset or actively contributing to its
more aggressive phenotype remains to be determined. In addition, this
work also demonstrates for the first time in vivo that Runx2, a key
regulator of bone development, could also have a functional role in
epithelial tissue. The potential functional role of RUNX2 in normal
mammary development awaits confirmation using a conditional-knockout
model. Overall, the findings reported in this paper suggest a clinically
relevant role for RUNX2 in breast cancer that is worthy of further
investigation. 
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WT mice, there was a delay in ductal elongation, with a significant
reduction in the distance that epithelial structures extend through the
fat pad (Fig. 2C; WT n=28, Runx2 n=23, P=0.002). By 8 weeks of
age, MMTV-Runx2 females overcame this delayed elongation
phenotype but, at this stage, a reduction in tertiary side-branching
was evident (Fig. 2D). Quantification by counting the number of
ducts in histological sections showed that MMTV-Runx2 females
displayed over 30% fewer ducts than controls (Fig. 2D; WT n=15,
Runx2 n=16, P=0.01). Hormone signalling plays a crucial role in
mammary gland development; however, ectopic Runx2 expression
does not significantly alter the number of PR+ or ERα+ cells
(supplementary material Fig. S2). Neither does the observed
phenotype result from changes in lineage specification, because
transgenic and control animals have comparable proportions of basal
and luminal cells, as well as CK5 and CK18 populations
(supplementary material Fig. S3). Transgenic Runx2 expression
therefore perturbs normal development with delayed elongation and
reduced tertiary branching of the mammary epithelial tree in young
virgin females.
Ectopic Runx2 expression delays lobular alveolar
differentiation, resulting in a lactation defect
Although MMTV-Runx2 transgenic females developed normally,
were fertile and had normal litter sizes, mothers consistently failed
to nurse their pups, which then died with little or no milk in their
stomachs. WT and transgenic glands appeared phenotypically
similar at mid-pregnancy, with comparable levels of proliferation
(D12, Fig. 3B). However, defects in mammary gland architecture
were observed by late pregnancy, with reduced ductal side-
branching and alveolar expansion, and a failure of terminal
differentiation resulting in a significant reduction in mature alveolar
units (Fig. 3A). There was no difference in apoptosis of glands as
assessed by caspase-3; however, inappropriate cell cycling (Fig. 3B)
was seen in what should be a fully differentiated organ at lactation,
exemplifying the delayed development of the post-parturient gland.
The differentiation marker whey acidic protein (WAP; a constitutive
milk protein) was detected at much lower levels compared with in
WT (Fig. 3C,D) and was absent from areas showing high transgene
expression (Fig. 3C), demonstrating a block in terminal alveolar
differentiation.
Prolactin hormone activity is crucial for terminal differentiation,
which leads to normal milk-producing alveolar units during
pregnancy and lactation. Prolactin receptor (Prlr) expression was
reduced in pregnant and lactating MMTV-Runx2 glands (Fig. 4A).
Expression of proteins downstream of PRLR, namely ELF5 and p-
STAT5, were unaffected by RUNX2 overexpression during late
pregnancy (Fig. 4B). However, at the onset of lactation, ELF5 and
p-STAT5 levels were reduced in MMTV-Runx2 glands (Fig. 4C).
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Fig. 1. Expression of RUNX2 correlates with
ER/PR/HER2-negative human breast cancer. Invasive
breast carcinomas from a tumour tissue microarray
(TMA-1) were stained for RUNX2. (A) Scatterplot
showing the range of positive histoscores. Expression
was divided into RUNX2-negative (histoscore 0), -low
(histoscore 1-24) or -high (histoscore ≥25) in 416 breast
cancers. The dotted line at histoscore 25 demonstrates
the cut-off for RUNX2-high patients. Position on the y-
axis reflects the order in which samples were analysed.
(B) Kaplan-Meier of patient survival for 384 patients in A
for which follow-up data was available. Survival is plotted
for patients with high-RUNX2 tumours (n=21) and
negative/low-RUNX2 tumours (n=363). (C) Examples of
individual tumours stained for RUNX2 and ER, depicting
the reciprocal expression pattern. Boxed areas are
shown at higher magnification. (D) Significantly more
RUNX2-high cancers were ER-negative (P=0.005; chi-
square) and specifically associated with the triple-
negative (ER/PR/HER2-negative) group (P=0.008; chi-
square).
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This is an important observation; during late pregnancy, Runx2-
expressing tissue, although abnormally differentiated, was still able
to express factors crucial for normal alveolar development.
However, at lactation, Runx2 expression seems to inhibit ELF5 and
p-STAT5 expression, blocking their normal function of driving
alveologenesis. We also assessed GATA3 in the lactating transgenic
glands but saw no difference compared with the controls (data not
shown).
This lactation defect could not be rescued by co-fostering, in
which continued suckling activity is achieved in the presence of a
RESEARCH ARTICLE Disease Models & Mechanisms (2014) doi:10.1242/dmm.015040
Fig. 2. Transgenic expression of Runx2
perturbs pubertal mammary
development. (A) qRT-PCR of Runx2
throughout murine mammary development.
Expression levels relative to wild-type 12-
week-old virgins; data are means ± s.d. (P,
pregnant; L, lactating; inv, involution, d, day).
(B) qRT-PCR of Runx expression in
basal/myoepithelial and luminal epithelial
cell populations sorted by FACS based on
CD29 and CD24 surface markers (see text
for details). Runx1 is plotted on a different y-
axis owing to the higher levels of expression.
Runx3 expression was not detectable in
either population. Expression normalised to
Gapdh is relative to luminal Runx2; data are
means of three independent samples ± s.d.
(C) Whole-mounts of 6-week-old mammary
glands. Elongation from lymph node (LN) in
weight- and litter-matched WT glands is
greater than in MMTV-Runx2 glands. Ductal
elongation lengths as represented by the red
arrows are quantified in the box plot
(P=0.002; WT n=28; Runx2 n=23). Dots
represent outliers. (D) Whole-mounts of 8-
week-old MMTV-Runx2 glands reveal a
reduction in tertiary side-branching in Runx2
glands compared with WT glands. Number
of ducts per H&E section were counted for
each sample (inset images); graph shows a
significant reduction in average duct number
in Runx2 mammary glands (P=0.01; WT
n=15; Runx2 n=16). Dots represent outliers.
Whole-mounts, 6.5× magnification; H&Es,
40× magnification.
Table 1. The relationship between RUNX2 and clinicopathological characteristics of patients with breast cancer
Characteristic RUNX2-high RUNX2-low/negative P-value
Age (<50/>50) 8/14 113/281 0.440
Type (ductal/lobular/other*) 19/0/3 354/26/14 0.036
Tumour size (<20/21-50/>50 mm) 13/8/1 223/158/11 0.854
Grade (I+II/III) 10/11 244/150 0.189
Lymph-node involvement (no/yes) 13/9 218/171 0.779
ER status (ER–/ER+) 13/9 118/272 <0.005
PR status (PR–/PR+) 16/6 193/196 <0.002
HER2 status (HER2–/HER2+) 20/1 321/69 0.125
Ki-67 status (low/high) 15/7 292/97 0.470
Necrosis (not necrotic/necrotic) 7/15 180/202 0.162
TUNEL (low apoptosis/high apoptosis) 10/9 210/164 0.763
KLINTRUP (low grade/high grade) 15/7 276/106 0.679
Lymphocyte infiltrate
(i) CD4 (low/medium/high) 7/3/12 165/84/144 0.256
(ii) CD8 (low/medium/high) 8/2/12 103/145/145 0.029
Plasma cell infiltrate
(i) CD20 (low/medium/high) 9/3/10 196/57/140 0.635
(ii) CD138 (low/medium/high) 10/2/10 207/51/134 0.542
Macrophage infiltrate (CD68: low/medium/high) 9/6/7 92/142/156 0.184
Vascular invasion (low/medium/high) 8/5/9 119/134/125 0.471
ER, oestrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2.
KLINTRUP score is a marker of inflammatory marker. 
*Other breast cancer types include medullary, mixed type, tubular, cribiform.
Results of clinicopathological scoring and immune infiltrate as previously published (Mohammed et al., 2012a; Mohammed et al., 2012b; Mohammed et al.,
2012c). 
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lactating foster mother (Fig. 5A). However, transgenic females with
multiple pregnancies (≥4) could rear small litters. Multiparous
Runx2 glands had more mature alveolar units, reduced RUNX2
expression and a reciprocal rise in WAP expression compared with
single-parous Runx2 females (Fig. 5). Interestingly, areas of
multiparous glands that expressed the transgene still showed delayed
development and a reduction in ELF5 and p-STAT5 (supplementary
material Fig. S4). Therefore, ectopic Runx2 elicits a lactation defect
by inhibiting terminal differentiation possibly by suppressing the
normal function of the PRLR pathway.
Mammary glands of aged MMTV-Runx2 females display pre-
neoplastic changes
Although we observed developmental perturbation, the ultimate aim
of our model was to explore the potential oncogenic role of Runx2
in mammary epithelium. Transgene expression in aged females
produced a dramatic and significant (P<0.001) expansion of
epithelial tissue with atypical hyperplastic and pre-neoplastic
lesions. Of 47 MMTV-Runx2 females aged between 16 and 24
months, 26 (55%) displayed alveolar expansion with focal or diffuse
hyperplasia and dilated ducts filled with secretory material
(Fig. 6A,B). Only 5/33 (15%) wild-type controls exhibited similar
characteristics. This phenotype was observed in both virgin
(n=18/31; 58%) and parturient (n=8/16; 50%) transgenic females;
therefore, hyperplasia was not a consequence of abnormal involution
and/or clearing of alveolar tissue. Expanded epithelial tissue often
manifested as secretory hyperplastic areas (Fig. 6B) with abnormal
features such as distorted acini with lobular fibrosis, chronic
inflammatory cell infiltrate and focal squamous metaplasia (Fig. 6C-
I), and as alveolar hyperplasia with luminal cells exhibiting large
nuclei and prominent nucleoli (Fig. 6C-II,C-III). A low incidence of
multifocal ductal carcinoma in situ (DCIS, n=3/47; 6%) was
observed in MMTV-Runx2 females (Fig. 6D), whereas no DCIS
were seen in control glands (0/33). SMA staining showed that these
were non-invasive lesions (Fig. 6D; n=3). Prevalent hyperplastic
lesions were negative for ER, PR (Fig. 6E; n=11) and HER2
(Fig. 6E; n=4). Interestingly, lesions were positive for MYC
(Fig. 6E; n=4), which has been shown previously to act
cooperatively with RUNX2 to drive T-cell lymphoma (Blyth et al.,
2006). Therefore, ectopic Runx2 elicits long-term remodelling of the
mammary gland promoting development of pre-neoplastic changes
in the epithelium.
DISCUSSION
Runx2 exerts a dominant oncogenic role in T-cell lymphomas (Blyth
et al., 2001; Blyth et al., 2006); however, little evidence about its
role in primary epithelial cancers has been described. Work on well-
characterised breast cancer cell lines has shown that RUNX2 can
influence the behaviour of these cells and the response of host
tissues following orthotopic injection to bone (Barnes et al., 2004;
Javed et al., 2005; Pratap et al., 2008), but this work has been
limited to a few cell lines. We now describe the first in vivo study
of the pro-oncogenic effects of RUNX2 in breast epithelium.
High RUNX2 expression is limited to a subpopulation of breast
cancer: it significantly associates with triple-negative (ER/PR/
HER2-negative) disease and correlates with poorer patient survival.
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Fig. 3. Ectopic RUNX2 expression leads to delayed
differentiation and a lactation defect. (A) Whole-mount and
histological analysis of MMTV-Runx2 glands (n=11) during late
pregnancy (D17 pregnant) reveals a reduction in side-branching
and alveolar expansion compared with WT (n=14), and failure to
form mature alveolar units during lactation (WT n=13; Runx2
n=11). (B) Ki67 staining of WT and MMTV-Runx2 glands at 
day 12 (D12) pregnancy (n=4 each), late pregnancy (D17P; 
n=6 each) and day 1 of lactation (D1; WT n=6; Runx2 n=7).
(C) Immunohistochemistry of whey acidic protein (WAP) and
RUNX2 on serial sections at day 1 lactation in WT (n=6) and
MMTV-Runx2 (n=7) glands illustrates their reciprocal expression
pattern. (D) Quantification of Wap mRNA with dramatically less
Wap in Runx2 glands at late pregnancy (d17P) and lactation (d1L);
data are means ± s.d. normalised to HPRT relative to WT virgin.
Whole-mounts, 8× magnification; H&Es, 200× magnification; IHC
images, 100× magnification in B and 200× magnification in C.
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Its potential as a putative prognostic marker in this subtype is
tantalising but, owing to the small number of positive samples,
requires testing in a larger cohort. Notably, expression of RUNX2 is
specifically observed in cell lines of the ‘basal-like’ subtype
(ER/PR/HER2-negative) and not in those derived from ‘luminal-
like’ tumours (Lau et al., 2006). Moreover, MMTV-Runx2 failed to
promote tumorigenesis in MMTV-PyMT and MMTV-ErbB2 models
(not shown), which have been molecularly compared to luminal
(ER+) breast cancers (Herschkowitz et al., 2007), again highlighting
its role in subtype-specific disease. The Frenkel group (Chimge et
al., 2011; Khalid et al., 2008) also showed that expression of
RUNX2 and its target genes inversely correlated with ER
expression, whereas overexpression of ER in MDA-MB-231 cells
inhibited RUNX2. Although these results are concordant with a
small study showing that RUNX2 is absent in ER+ breast cancer
(Onodera et al., 2010), they contrast to one in which RUNX2
expression was specifically found in ER+ tumours (Das et al., 2009).
Interestingly, RUNX2 has never been identified in transcriptomic
analyses of breast cancer, but this might be due to problems with
RUNX2 probe sets, and, using a RUNX2 metagene as a surrogate
for RUNX2 activity, it has been shown that high expression of
RUNX2-target genes correlates with basal-like breast cancers
(Chimge and Frenkel, 2013), in support of our own conclusions.
A mammary-specific Runx2 transgenic model was generated to
definitively test its role in primary epithelium. The most striking
phenotype of MMTV-Runx2 mice was extensive changes
characterised by hyperplasia, dysplasia and lesions consistent with
a pre-neoplastic phenotype in aged females, observed in both virgin
and parturient females. Some of the changes, even in virgin animals,
resemble the secretory phenotype of a pregnant gland, suggesting
attenuation of control mechanisms that keep mammary stem or
progenitor cells quiescent, ultimately disrupting epithelial
homeostasis. Such an effect could be intrinsic to the epithelial
compartment or relate to how persistent Runx2 expression affects
the mammary environment. RUNX2 regulates the expression of
extracellular matrix proteins (Komori, 2010) and cross-talk between
epithelium and stroma is important for development and progression
of breast cancer (Place et al., 2011). Our results reveal the potential
of Runx2 to exert oncogenic effects in primary epithelium; however,
the lack of overt carcinoma in mice suggests that additional genetic
mutations are required. Indeed we note high levels of MYC in the
lesions, which has been shown previously to be a strong
RESEARCH ARTICLE Disease Models & Mechanisms (2014) doi:10.1242/dmm.015040
Fig. 4. Ectopic Runx2 inhibits ELF5
and p-STAT5 during lactation.
(A) Prolactin receptor (Prlr) mRNA
expression at pregnancy (d8P, d17P) and
lactation (d1L) in Runx2 and WT glands;
data are means ± s.d., normalised to
HPRT and relative to WT virgin. (B) ELF5
and p-STAT5 protein levels are not
affected in MMTV-Runx2 glands at late
pregnancy (day 17) but, during lactation,
Runx2 overexpression causes a reduction
in levels of ELF5 and p-STAT5 (C). Each
image is representative of n≥3 mice.
Boxed areas are shown at higher
magnification. Scale bars: 10 μm (5 μm in
higher-magnification images).
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collaborating event with RUNX2 in lymphoid tumours (Blyth et al.,
2001; Blyth et al., 2006). Alternatively, because RUNX2 expression
correlates with basal-like human disease, it could be that the
MMTV-driven expression in the transgenic model does not
effectively target the most susceptible cell population. Interestingly,
the hyperplastic lesions were negative for ER, PR and HER2
expression, which might be related to the role of RUNX2 in
antagonising ER signalling (Chimge et al., 2012; Chimge and
Frenkel, 2013; Khalid et al., 2008).
Expression of the Runx genes is tightly controlled in mammary
epithelia, both spatially and temporally. In keeping with this,
RUNX2 regulates a number of genes involved in mammary function
(Inman et al., 2005; Inman and Shore, 2003). Cells of the
basal/myoepithelial lineage express significantly higher levels of
Runx1 and Runx2 than luminal cells. Because this population
harbours stem cells capable of generating whole glands from a
single cell (Shackleton et al., 2006), it is tempting to speculate that
Runx genes might regulate mammary stem cell or progenitor
function (Ferrari et al., 2013), especially because Runx genes are
already known to have a homeostatic role in haematopoietic stem
cells (Swiers et al., 2010). Expression was higher in the virgin gland
and fell during pregnancy and lactation. Consistent with this
functional pattern of expression, ectopic Runx2 prevented terminal
differentiation of mammary cells in late pregnancy and inhibited
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Fig. 5. Runx2-induced lactation
failure is partially rescued by
multiple parities. Transgenic
females were housed with co-
fostered WT females to achieve
continued suckling from pups.
Representative images for single
parous (A) and multiparous (≥4
pregnancy) (B) co-fostered females
at day 1 lactation. Whole-mounts
show the retarded development in
transgenics, although Runx2
multiparous glands have more
mature alveolar formation, with
glands evidently fuller and producing
more WAP (B) than Runx2 single-
parity females (A). Multiparous
transgenic glands proportionally
express less RUNX2 than single-
parity glands, which is reciprocal to
the higher levels of WAP as shown
in serial sections in A and B. Boxed
areas are shown at higher
magnification. Single-parous
females: WT n=6, Runx2 n=7;
multiparous females: WT n=3,
Runx2 n=3. Quantification of RUNX2
positivity per total epithelium in
multiparous (grey) and single-parous
(black) glands is given in the bar
graph (P=0.0001; single parous n=5;
multiparous n=3). Scale bars in
wholemounts: 2 mm in A and 1 mm
in B; scale bars in IHC images: 20
µm (10 µm in higher-magnification
images).
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development of alveoli, with resultant agalactia. Interestingly,
multiple pregnancies can partially rescue the lactation defect. Gil
Smith and colleagues have described the existence of mammary
progenitor cells that persist in the mammary gland after involution
and can contribute to the formation of alveolar units at subsequent
pregnancies (Boulanger et al., 2005; Wagner et al., 2002). Given that
the Runx2 transgene shows a mosaic pattern of expression, one
possible explanation is that parity-induced progenitor cells
expressing the transgene have a selective disadvantage and are
outcompeted over multiple pregnancies, with ultimate recovery of
function.
The phenotype we observed in MMTV-Runx2 lactating females
is reminiscent of knockout models downstream of PRLR signalling,
such as Elf5 and Stat5. PRLR signalling is essential for terminal
differentiation and lactation function, and mammary-specific
deletion models of Elf5 and Stat5 display abnormal alveologenesis
and lactation defects (Choi et al., 2009; Liu et al., 1997; Oakes et
al., 2008). It is of note that there is a reduction in ELF5 and p-
STAT5 in Runx2-expressing glands with aberrant alveologenesis.
Under normal circumstances, Runx2 might be suppressed to allow
proper PRLR signalling and lactation, whereas, in the
overexpression model, Runx2 inhibits the PRLR cascade,
culminating in a lactation deficiency.
Thus, ectopic expression of Runx2 perturbs development and
differentiation in the mouse mammary gland, suggesting that levels
must be tightly controlled for normal development. Transgenic
expression also predisposes to precancerous lesions, showing for the
first time a pro-oncogenic role in mammary epithelium. In this
regard, RUNX2 is significantly associated with triple-negative
breast cancer and patients with higher RUNX2 expression have
poorer survival rates. Whether RUNX2 is acting as a neutral
biomarker for this poor prognostic subset or actively contributing to
a more aggressive phenotype remains to be determined but is worthy
of further investigation with important clinical relevance.
MATERIALS AND METHODS
Transgenic mice
To generate MMTV-Runx2 mice, murine p1 Runx2 polyA cassette of Cbfa1-
G1 (Vaillant et al., 1999) was excised by EcoRV/XbaI digestion and cloned
into a 5.63-kb BmgBI-XbaI fragment of MMTV construct (kindly supplied
by Alexander Borowsky, UC Davis Comprehensive Cancer Center,
Sacramento, CA) (supplementary material Fig. S1A). pBluescript sequences
were removed by XhoI/SacII digestion. MMTV-Runx2p1 polyA insert was
purified, and linearised DNA microinjected into C57Bl/6 × CBA/Ca F2
embryos. All animal work was carried out under the Animal (Scientific
Procedures) Act 1986 and the EU Directive 2010 (PPL 60/4181).
Wholemount/histological analysis of mammary glands
Inguinal glands were dissected, fixed in Carnoy’s, rehydrated through
ethanol and stained with carmine alum or haematoxylin. Glands were
dehydrated, cleared in xylene, mounted in Permount (Thermo Fisher) and
captured with Zeiss stereomicroscope. For histological analysis, glands were
dissected into neutral buffered formalin and H&E stained.
Immunohistochemistry
Paraffin-embedded tissue sections were rehydrated before antigen retrieval
using pH 6 sodium citrate buffer (or 1 mM EDTA pH 8 for WAP). After
washing with Tris-buffered saline and blocking endogenous peroxidase,
sections were incubated for 1 hour at room temperature (RT) with the
following HRP-conjugated primary antibodies: anti-RUNX2 (Sigma
HPA022040; 1/100), anti-cytokeratin-5 (Covance PRB-160P; 1/500), anti-
cytokeratin-8/18 (Fitzgerald 20R-CP004; 1/500 overnight at 4°C), anti-ERα
(Santa Cruz sc-542; 1/250), PR (Santa Cruz sc-539; 1/250), anti-Ki67
(Thermo Fisher RM-9106-S1; 1/250), anti-ELF5 (Santa Cruz sc-9645;
1/100), anti-p-STAT5 (Cell Signaling 9359S; 1/300), anti-SMA (Sigma
A2547; 1/6000), anti-c-MYC (Santa Cruz sc-764; 1/200), anti-HER2 (Cell
Signaling CS#2165; 1/400) and anti-WAP (Santa Cruz sc-14832; 1/2500).
Additional anti-RUNX2 antibodies were used for validation in human
samples (R&D Systems AF2006; Santa Cruz sc-10758x; MBL D130-3).
Anti-rabbit secondary (Dako EnVision) was used for all antibodies except
CK8/18 (anti-guinea pig; Sigma A9167, 1/600), SMA (Dako EnVision
mouse kit) and WAP/ELF5 (anti-goat; Impress goat kit). Sections were
incubated with secondary antibodies for 50 minutes at RT, treated with DAB
and counterstained with haematoxylin.
Quantitative RT-PCR
SYBR-Green-based quantitative PCR was carried out and data analysed
using MJ Chromo4 (Bio-Rad). Primers: Runx1 (Qiagen Quantitect
QT0010000380), Runx2 (Qiagen Quantitect QT00102193), Runx3-Fwd (5′-
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Fig. 6. Mammary glands of aged MMTV-Runx2 females display
abnormal hyperplastic and pre-neoplastic changes. (A) Representative
whole-mounts of aged MMTV-Runx2 and WT littermate controls (8×
magnification). (B) Representative images of H&E sections showing diffuse
hyperplasia in two independent MMTV-Runx2 transgenic glands with
evidence of secretory hyperplastic lesions and dilated ducts (100×
magnification). (C) Abnormal features observed in aged MMTV-Runx2
glands, such as distorted acini with lobular fibrosis and chronic inflammatory
cell infiltrate (I), and alveolar hyperplasia with luminal cells exhibiting large
nuclei and prominent nucleoli (II,III) (images shown at 400× magnification).
(D) Ductal carcinoma in situ (DCIS) in an MMTV-Runx2 female; middle panel
is higher magnification of boxed area. Smooth muscle actin (SMA) staining
shows an intact basal/myoepithelial layer. (E) Hyperplastic lesions are
negative for ER, PR and HER2 but show positivity for MYC as determined by
immunohistochemistry (400× magnification).
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GCACCGGCAGAAGATAGAAGAC-3′), Runx3-Rev (5′-GGTTTAAG -
AAGCCTTGGATTGG-3′), PrlR (Qiagen Quantitect QT00154154), WAP-
Fwd (5′-TTGAGGGCACAGAGTGTATC-3′), WAP-Rev (5′-TTTGCGGG -
TCCTACCACAG-3′), HPRT (Qiagen Quantitect QT00166768) and
GAPDH (PrimerDesign kit). All reactions were performed in triplicate, and
expression normalised to HPRT/GAPDH.
Western blot
Nuclear extracts were prepared from tissue using NE-PER Nuclear and
Cytoplasmic Extraction Reagents (Thermo Scientific). 20 μg extract was
resolved on 10% NuPAGE Novex Bis-Tris gels (Invitrogen) and transferred
to Hybond-ECL nitrocellulose membranes (Amersham). Membranes were
probed with RUNX2 (Sigma), ERK (Cell Signaling) and GAPDH (Cell
Signaling).
Cell lines
Epithelial cells were extracted from pregnant mammary glands for RUNX2
western. Runx2−/− mouse embryonic fibroblasts (Rx2KO MEFs) (Kilbey et
al., 2007) were used as negative control. MDA-MB-231 was purchased from
American Type Culture Collection. MDA-MB-231 cells were transfected
with RUNX2 shRNA and scrambled control (HuSHTM, Origene) through
electroporation using Nucleofector Kit V program X-013 (Amaxa, Lonza).
For immunohistochemistry, cells were fixed with 2% paraformaldehyde for
15 minutes. After centrifugation, pellets were resuspended in 200 μl of 3%
UltraPureTM low-melting agarose (Invitrogen) and left for 20 minutes at RT
to solidify. The agarose plug in 70% ethanol was embedded in paraffin
blocks and stained as above.
Flow cytometry/cell sorting
Mammary glands were dissected from 12-week-old virgin females (n≥3) to
obtain epithelial cells, and labelled with CD24-PE, CD29-FITC, CD31-APC
and CD45-APC (BD Biosciences) for flow cytometry (Shackleton et al.,
2006). Live Lin– cells (DAPI/CD31/CD45-negative) were gated on
FACSAria (BD Biosciences) for CD24hiCD29lo (luminal) and
CD24hiCD29hi (basal/myoepithelial) cells using FlowJo software. For cell
sorting, these populations were collected and processed for qRT-PCR.
Human tissue microarray
Expression studies in human tissues were ethically approved [LREC Ref:
Project Number 02/63(1) R&D project: 02PA002 and REC Ref: Project
Number 02/SG007(10), R&D project: RN07PA001]. Tissue microarrays
were already available. 0.6 mm2 breast cancer tissue cores, identified by a
pathologist (Dr Elizabeth Mallon, Southern General Hospital), were
removed from representative areas of tumours taken from patients at surgical
resection. Tissue microarray blocks were constructed in triplicate. All
patients in both the training set (TMA-1) and validation cohorts (TMA-2)
were selected from a retrospective audit of clinical characteristics of 1743
patients diagnosed with operable invasive breast carcinoma between 1980
and 1999 in the Greater Glasgow and Clyde area, where clinical specimens
were available. Cohort characteristics were similar (Table 2).
Patients received standard adjuvant treatment according to protocols.
Follow-up details included information on clinical attendances, recurrence
and metastasis, date and cause of death as well as adjuvant therapy details.
ER, PR (Mohammed et al., 2012a) and HER2 status (Mohammed et al.,
2012c), and immune and inflammatory infiltrate (Mohammed et al., 2012b)
were already available. Tissue work was conducted with strict adherence to
REMARK Criteria (Altman et al., 2012), where inclusion criteria was
availability of clinical information and tissue for analysis, and exclusion
criteria was missing data and tissue. Because this was a retrospective cohort,
treatment was chosen by the health care team according to what was most
appropriate for the patient at the time. Tissue microarrays were stained for
RUNX2 by immunohistochemistry. Anti-RUNX2 antibody validation was
confirmed in MDA-MB-231 cells with shRUNX2 knockdown stained using
the same protocol as the TMA, and by western blot (supplementary material
Fig. S5). RUNX2 was quantified using weighted histoscore method to give
a value of 0-300 (Kirkegaard et al., 2006). 230 cores (15% of total core
number) were scored independently for RUNX2 by two observers (L.M. and
N.F.) who were blind to patient’s outcome and each other’s score.
Agreement between observers, calculated using interclass correlation
coefficient (ICCC), was 0.84, classed as very good. L.M. then scored all
cores and this data was used in the analysis.
Statistical analysis
Statistical significance (P<0.05) of differential findings between
experimental groups was determined by Student’s t-test using SigmaPlot 8.0.
For human studies, SPPS19 (Chicago) was used and disease-specific
survival rates generated using Kaplan-Meier. Log-rank test compared
significant differences between subgroups using univariate analysis.
Interrelationships between clinical parameters, PR and HER2 status, were
calculated using chi-square test. Missing data was not boot-strapped and
therefore not considered in the analysis.
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